The Russian Ministry of Health issued a registration certificate for the generic of original semaglutide, the patent for which is held by Novo Nordisk until 2035.
“Ozempik” is included in the list of Vital and Essential Drugs, in 2022, the Ministry of Health of russia registered its ceiling price of 5800 rubles. At the same time, in the fall of 2022, the manufacturer Novo Nordisk notified Roszdravnadzor about the decision to stop supplying the drug to russia from 2024. It is reported that the drug is already in defect in russia.
The patent for the semaglutide molecule is valid until 2031, also two components of the substance are protected until 2025 and 2038. Therefore, the launch of the drug on the market to ensure patient safety depends on the decisions of the russian government. The current legislation provides for a compulsory license procedure for this purpose.
